Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients
Status:
Unknown status
Trial end date:
2019-10-30
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy of 12 or 8 weeks treatment with Grazoprevir/Elbasvir in Early Chronic
Hepatitis C GT1,4 in HIV co-infected patients and evaluate the safety and tolerability of
Grazoprevir + Elbasvir in HIV-HCV co-infected patients.